Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03400501 · ClinicalTrials.gov registry record · Early Phase 1
Reducing the Risk of Metabolic Decompensation in Diabetic Adolescents by Supervised School Administration of Insulin
A Early Phase 1 study, sponsored by Yale University.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 32
- Enrollment target
NCT03400501 is a Early Phase 1 study that has completed, run by Yale University. The registered enrollment target is 32 participants.
The verdict
NCT03400501, a Early Phase 1 study, has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 32 participants
- Enrollment target
Study Summary
This is a pilot study to examine and compare the efficacy of supervised injections of long acting insulins degludec and glargine to protect youth with poorly controlled type 1 diabetes (T1D) from development of ketones.
Interventions
- DRUG Insulin Glargine
- DRUG Insulin Degludec
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2017-10-01 |
| Est. Completion | 2021-06-07 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03400501
The ClinicalTrials.gov registry entry for NCT03400501 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Insulin Glargine is the first listed.
NCT03400501 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03400501 about?
NCT03400501 is a clinical study titled "Reducing the Risk of Metabolic Decompensation in Diabetic Adolescents by Supervised School Administration of Insulin". This is a pilot study to examine and compare the efficacy of supervised injections of long acting insulins degludec and glargine to protect youth with poorly controlled type 1 diabetes (T1D) from development of ketones.
What is the current status of trial NCT03400501?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 32 participants. The study started on 2017-10-01. Estimated completion is 2021-06-07.
What interventions are being tested in trial NCT03400501?
The interventions under investigation include: Insulin Glargine (DRUG), Insulin Degludec (DRUG).
Who is sponsoring clinical trial NCT03400501?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.